Actively Recruiting
Phase I Study of AL58805 Dose Tolerance and Drug Behavior in Adults With Advanced Tumors
Led by Advenchen Laboratories Nanjing Ltd. · Updated on 2025-09-17
40
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of the drug AL58805 in patients who have advanced solid tumors and limited treatment options. This Phase I trial aims to find the maximum tolerated dose and identify dose-limiting toxicities while studying how the drug behaves in the body through pharmacokinetic testing. The study focuses on patients whose tumors have progressed despite standard treatments or who cannot tolerate those treatments. Participants will receive oral doses of AL58805, administered once or twice daily with doses ranging from 20 mg to 60 mg. The study involves escalating doses to understand how much of the drug can be safely given. The treatment period includes monitoring for side effects and drug levels in the blood to evaluate tolerance and toxicity reversibility. Throughout the study, participants will undergo regular health assessments including blood tests to measure drug concentration and organ function. Researchers will monitor for dose-limiting toxicity from the start of treatment until 28 days after the first dose. The study also collects data on drug absorption and clearance within one month after dosing. Participants are expected to be involved throughout the treatment and follow-up periods until safety and pharmacokinetic goals are met.
CONDITIONS
Brief Title
A Study of AL58805 in Patients With Advanced Tumors
Research Team
L
Li Sha Qi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here